Arcellx (ACLX) Preferred Shares Issued (2021)

Arcellx (ACLX) recorded quarterly Preferred Shares Issued of $37.4 million in Q2 2021, down 54.3% quarter-over-quarter from $81.8 million in Q1 2021.

Arcellx (ACLX) Preferred Shares Issued (2021) Analysis & Trends

Arcellx's Preferred Shares Issued history runs 1 years deep, the most recent figure standing at $37.4 million for Q2 2021.

In Q2 2021, Preferred Shares Issued changed N/A year-over-year to $37.4 million; the TTM figure through Dec 2021 stood at $119.1 million (changed N/A YoY), while the FY2021 annual figure was $119.1 million, changed N/A from the prior year.
Preferred Shares Issued was $37.4 million for Q2 2021 at Arcellx, down from $81.8 million in the prior quarter.
In the past five years, Preferred Shares Issued ranged from a high of $81.8 million in Q1 2021 to a low of $37.4 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares Issued (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Arcellx	6.48 Bn	6.48 Bn	-	-

Download Data